VANGUARD GROUP INC 13D and 13G filings for Cytek Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 5:40 pm Sale | 2026-03-13 | 13G | CYTEK BIOSCIENCES INC CTKB | VANGUARD GROUP INC | 0 0.000% | -7,765,138 (Position Closed) | Filing |
| 2025-07-29 11:21 am Sale | 2025-06-30 | 13G | CYTEK BIOSCIENCES INC CTKB | VANGUARD GROUP INC | 7,765,138 6.130% | -1,856,870 (-19.30%) | Filing |
| 2025-04-30 10:57 am Sale | 2025-03-31 | 13G | CYTEK BIOSCIENCES INC CTKB | VANGUARD GROUP INC | 9,622,008 7.510% | -2,268,692 (-19.08%) | Filing |
| 2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | CYTEK BIOSCIENCES INC CTKB | VANGUARD GROUP INC | 11,890,700 8.770% | 4,119,633 (+53.01%) | Filing |
| 2023-02-09 11:16 am Purchase | 2022-12-30 | 13G | CYTEK BIOSCIENCES INC CTKB | VANGUARD GROUP INC | 7,771,067 5.760% | 7,771,067 (New Position) | Filing |